TAA 08
Alternative Names: TAA-08Latest Information Update: 08 Jun 2022
At a glance
- Originator PersonGen Biotherapeutics
- Class CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Atherosclerosis; Diabetes mellitus; Fibrosis; Hepatic fibrosis; Osteoarthritis; Sarcopenia
Most Recent Events
- 01 Jun 2022 Early research in Atherosclerosis in China (Parenteral) before June 2022 (PersonGen BioTherapeutics pipeline, June 2022)
- 01 Jun 2022 Early research in Diabetes mellitus in China (Parenteral) before June 2022 (PersonGen BioTherapeutics pipeline, June 2022)
- 01 Jun 2022 Early research in Fibrosis in China (Parenteral) before June 2022 (PersonGen BioTherapeutics pipeline, June 2022)